Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethyl eicosapentaenoic acid - Mochida Pharmaceutical

Drug Profile

Ethyl eicosapentaenoic acid - Mochida Pharmaceutical

Alternative Names: eicosapentaenoic acid ethyl ester; EPA-E; Epadel; ethyl icosapentaenoate; ethyl icosapentate; MND 2119; MND-21

Latest Information Update: 05 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mochida Pharmaceutical
  • Developer Mochida Pharmaceutical; Sumitomo Pharma
  • Class Antidementias; Antidepressants; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Antivirals; Eicosanoids; Esters; Omega 3 fatty acids; Reactive oxygen species; Small molecules; Vascular disorder therapies
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors; Phospholipase A2 inhibitors; Platelet aggregation inhibitors; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Hyperlipidaemia
  • Phase III Hypertriglyceridaemia
  • Phase II Alzheimer's disease

Most Recent Events

  • 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
  • 08 Mar 2022 Ethyl eicosapentaenoic acid is still in phase III trials for Hypertriglyceridaemia in China (NCT04239950)
  • 14 Jul 2021 Mochida Pharmaceutical completes phase III trial in Hypertriglyceridemia in Japan (PO) (NCT04221217)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top